Nexalin regains Nasdaq minimum bid price compliance, avoids delisting hearing risk
NXL•Nexalin regained compliance with Nasdaq’s $1.00 minimum bid price rule after closing above that level for 21 straight sessions from Aug. 31 to Sept. 29, 2026. A Nasdaq Hearings Panel granted continued listing, but the company must meet a $2.5 million stockholders’ equity threshold by Jan. 4, 2027.
1. Listing requirements
Nasdaq confirmed Nexalin’s stock closed above $1.00 for 21 consecutive sessions from Aug. 31 to Sept. 29, 2026. The Nasdaq Hearings Panel granted continued listing subject to the company meeting the bid price test and other requirements, including a $2.5 million stockholders’ equity threshold by Jan. 4, 2027.
